Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in Recurrent/Metastatic Nasopharyngeal Cancer
NCT05198531Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bemosesuglimab in nasopharyngeal carcinoma (NPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
bemosesuglimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05198531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198531.